June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Extended Release of Bevacizumab Through Nanoliposomes for Treating Ocular Angiogenesis
Author Affiliations & Notes
  • Devi Kalyan Karumanchi
    Center for Biochemical and Biophysical Studies, Northern Illinois University, Dekalb, Illinois, United States
    The Drug Delivery Company, Baltimore, Maryland, United States
  • Jeffrey Benner
    The Drug Delivery Company, Baltimore, Maryland, United States
  • Steven Cohen
    The Drug Delivery Company, Baltimore, Maryland, United States
  • Yana Skrypai
    Center for Biochemical and Biophysical Studies, Northern Illinois University, Dekalb, Illinois, United States
  • Alex Thomas
    Center for Biochemical and Biophysical Studies, Northern Illinois University, Dekalb, Illinois, United States
  • Ajinboye Uwensuyi
    Center for Biochemical and Biophysical Studies, Northern Illinois University, Dekalb, Illinois, United States
  • Elizabeth R Gaillard
    Center for Biochemical and Biophysical Studies, Northern Illinois University, Dekalb, Illinois, United States
  • Footnotes
    Commercial Relationships   Devi Kalyan Karumanchi, Northern Illinois University (P); Jeffrey Benner, The Drug Delivery Company (F); Steven Cohen, The Drug Delivery Company (F); Yana Skrypai, None; Alex Thomas, None; Ajinboye Uwensuyi, None; Elizabeth Gaillard, Northern Illinois University (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4102. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Devi Kalyan Karumanchi, Jeffrey Benner, Steven Cohen, Yana Skrypai, Alex Thomas, Ajinboye Uwensuyi, Elizabeth R Gaillard; Extended Release of Bevacizumab Through Nanoliposomes for Treating Ocular Angiogenesis
      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):4102.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To develop a sustained release ocular drug delivery system to improve the release kinetics of Bevacizumab to treat ocular angiogenesis

Methods : Fluorescent labeled Bevacizumab (Avastin) was encapsulated in cocktail of different liposomal formulations. The liposomes were examined for hydrodynamic diameter, surface morphology, thermal stability and in vitro release using dynamic light scattering, transmission electron microscopy, differential scanning calorimetry and dissolution studies respectively. Dutch belted rabbits were used as animal models to compare controls with various strategies like liposomal injections, hydrogels and drug depot implants to improve the sustained release of Avastin over a longer period of time. Sustained release and diffusion of the fluorescent labeled antibodies in the rabbit’s eye was screened using a Fluorotron spectrofluorometer on a weekly basis.

Results : The liposomal formulations after extrusion exhibited a narrow size distribution of approximately 100-150 nm in diameter with around 85-92% encapsulation efficiency. From the in vitro drug release studies, we observed a timed release over a period of 6-8 months depending on the composition of the formulation. Through trapping the bevacizumab loaded liposomes in hydrogels and drug depot implants, we were able to extend the release to about 7-8 months in vitro. In vivo drug release kinetics and distribution using Dutch belted rabbits as animal models to test the efficacy of liposomes, hydrogels and the implant are currently in progress.

Conclusions : Liposomal compositions were modified to improve the stability and to extend the time of release. Abrishami et al have been able to obtain a sustained release of the anti-VEGF drugs up to a period of 42 days. We have been successful in encapsulating a model protein into our stable liposomal formulations and employ different intravitreal administration strategies to attain a controlled release over a period of 6-8 months in vitro. Currently, we are studying the in vivo drug release kinetics and distribution using Dutch belted rabbits as animal models. With this study, our efforts would be to decrease the frequency of intravitreal injections from 12 to 2 per year, thereby effectively making the treatment more economical.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×